European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation

Coadministration of Dabigatran Etexilate and Atorvastatin

(2013) Joachim Stangier et al.   American Journal of Cardiovascular Drugs

“R” for “Renal” and for “Risk”

(2013) A. John Camm et al.   CIRCULATION

Impact of Daily Dosing Frequency on Adherence to Chronic Medications Among Nonvalvular Atrial Fibrillation Patients

(2012) François Laliberté et al.   ADVANCES IN THERAPY

Interpretation of Point-of-care INR Results in Patients Treated with Dabigatran

(2012) Joanne van Ryn et al.   AMERICAN JOURNAL OF MEDICINE

Safe Use of Hemodialysis for Dabigatran Removal before Cardiac Surgery

(2012) Matthew R Wanek et al.   ANNALS OF PHARMACOTHERAPY

Dabigatran Association With Higher Risk of Acute Coronary Events

(2012) Ken Uchino   ARCHIVES OF INTERNAL MEDICINE

Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding

(2012) T. E. Warkentin et al.   BLOOD

Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin

(2012) Sebastian Härtter et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Bleeding After Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in Atrial Fibrillation Patients Following Myocardial Infarction and Coronary Intervention

(2012) Morten Lamberts et al.   CIRCULATION

Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial

(2012) Stefan H. Hohnloser et al.   CIRCULATION

Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin

(2012) Jeff S. Healey et al.   CIRCULATION

Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation

(2012) Jonathan P. Piccini et al.   CIRCULATION

Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial

(2012) Antonio L. Dans et al.   CIRCULATION

Efficacy and Safety of Periprocedural Dabigatran in Patients Undergoing Catheter Ablation of Atrial Fibrillation

(2012) Kenichi Kaseno et al.   CIRCULATION JOURNAL

2012 focused update of the ESC Guidelines for the management of atrial fibrillation

(2012) et al.   EUROPACE

A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation

(2012) Stephen Andrew LaHaye et al.   EUROPEAN HEART JOURNAL

Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study

(2012) Leif Friberg et al.   EUROPEAN HEART JOURNAL

Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial

(2012) Stefan H. Hohnloser et al.   EUROPEAN HEART JOURNAL

Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation

(2012) J. M. L. Hendriks et al.   EUROPEAN HEART JOURNAL

A comparison of bleeding complications post-ablation between warfarin and dabigatran

(2012) David Snipelisky et al.   JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY

New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes

(2012) Raffaele De Caterina et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Feasibility and Safety of Dabigatran Versus Warfarin for Periprocedural Anticoagulation in Patients Undergoing Radiofrequency Ablation for Atrial Fibrillation

(2012) Dhanunjaya Lakkireddy et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model

(2012) I. PRAGST et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate

(2012) M. D. LAMBOURNE et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Stroke and Bleeding in Atrial Fibrillation with Chronic Kidney Disease

(2012) Jonas Bjerring Olesen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran

(2012) Robert G. Hart et al.   STROKE

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban

(2012) Raphael Marlu et al.   THROMBOSIS AND HAEMOSTASIS

Impact of dabigatran on a large panel of routine or specific coagulation assays

(2012) Séverine Robert et al.   THROMBOSIS AND HAEMOSTASIS

Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice

(2012) Gregory Y. H. Lip et al.   THROMBOSIS AND HAEMOSTASIS

Evaluation of Prothrombin Complex Concentrate and Recombinant Activated Factor VII to Reverse Rivaroxaban in a Rabbit Model

(2011) Anne Godier et al.   ANESTHESIOLOGY

Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: Thrombin or factor-Xa inhibitors. Recommendations of the Working Group on perioperative haemostasis and the French Study Group on thrombosis and haemostasis

(2011) Pierre Sié et al.   Archives of Cardiovascular Diseases

Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation

(2011) John W. Eikelboom et al.   CIRCULATION

Dabigatran Versus Warfarin in Patients With Atrial Fibrillation

(2011) Rangadham Nagarakanti et al.   CIRCULATION

Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate

(2011) Elise S. Eerenberg et al.   CIRCULATION

Rivaroxaban

(2011) Wolfgang Mueck et al.   CLINICAL PHARMACOKINETICS

Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment

(2011) K. A. A. Fox et al.   EUROPEAN HEART JOURNAL

ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)

(2011) et al.   EUROPEAN HEART JOURNAL

Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial

(2011) J. Oldgren et al.   EUROPEAN HEART JOURNAL

The Use of Dabigatran Immediately After Atrial Fibrillation Ablation

(2011) ROGER A. WINKLE et al.   JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY

Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Rivaroxaban

(2011) Kenneth Todd Moore et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban

(2011) M. J. Gnoth et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Severe Renal Impairment and Stroke Prevention in Atrial Fibrillation

(2011) Ricarda Marinigh et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial

(2011) K.-H. LIESENFELD et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents

(2011) M. LEVI et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Apixaban in Patients with Atrial Fibrillation

(2011) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome

(2011) John H. Alexander et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban in Patients with a Recent Acute Coronary Syndrome

(2011) Jessica L. Mega et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hemostatic Therapy in Experimental Intracerebral Hemorrhage Associated With the Direct Thrombin Inhibitor Dabigatran

(2011) Wei Zhou et al.   STROKE

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)

(2010) Christian T. Ruff et al.   AMERICAN HEART JOURNAL

Warfarin Use and Outcomes in Patients with Atrial Fibrillation Complicating Acute Coronary Syndromes

(2010) Renato D. Lopes et al.   AMERICAN JOURNAL OF MEDICINE

Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor

(2010) Dagmar Kubitza et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate

(2010) Joachim Stangier et al.   CLINICAL PHARMACOKINETICS

Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)

(2010) et al.   EUROPACE

Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers

(2010) Koichiro Ogata et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effects of Food on the Pharmacokinetics of Edoxaban, an Oral Direct Factor Xa Inhibitor, in Healthy Volunteers

(2010) Jeanne Mendell et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Guidelines for the Management of Spontaneous Intracerebral Hemorrhage

(2010) Lewis B. Morgenstern et al.   STROKE

Assays for Measuring Rivaroxaban: Their Suitability and Limitations

(2010) Edelgard Lindhoff-Last et al.   THERAPEUTIC DRUG MONITORING

Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity

(2010) Joachim Stangier et al.   THROMBOSIS AND HAEMOSTASIS

Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects

(2009) Joachim Stangier et al.   CLINICAL PHARMACOKINETICS

In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction Studies

(2009) L. Wang et al.   DRUG METABOLISM AND DISPOSITION

Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial

(2009) R. D. Lopes et al.   EUROPEAN HEART JOURNAL

Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data

(2009) Rikke Sørensen et al.   LANCET

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

(2009) Lars Wallentin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects

(2008) Dagmar Kubitza et al.   CURRENT MEDICAL RESEARCH AND OPINION

Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans

(2008) N. Raghavan et al.   DRUG METABOLISM AND DISPOSITION

Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment

(2008) P. P. Karjalainen et al.   EUROPEAN HEART JOURNAL

Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation

(2008) et al.   EUROPEAN HEART JOURNAL

Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation

(2008) R D Lopes et al.   HEART